# EDGAR Filing Document

**Accession Number:** 0001512762
**File Stem:** 0001193125-23-007361
**Filing Date:** 2023-1
**Character Count:** 5149
**Document Hash:** d9e46eabde4838c5d0757a49676a2c5a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-007361.hdr.sgml**: 20230113

**ACCESSION NUMBER**: 0001193125-23-007361

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230113

**DATE AS OF CHANGE**: 20230112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coherus BioSciences, Inc.
- **CENTRAL INDEX KEY:** 0001512762
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 273615821
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36721
- **FILM NUMBER:** 23526916

**BUSINESS ADDRESS:**
- **STREET 1:** C/O DENNIS M. LANFEAR
- **STREET 2:** 333 TWIN DOLPHIN DR, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** (650) 649-3530

**MAIL ADDRESS:**
- **STREET 1:** C/O DENNIS M. LANFEAR
- **STREET 2:** 333 TWIN DOLPHIN DR, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioGenerics, Inc.
- **DATE OF NAME CHANGE:** 20110210

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 9, 2023

------

## COHERUS BIOSCIENCES, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36721** | **27-3615821** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification Number)** |

---

#### 333 Twin Dolphin Drive, Suite 600

#### Redwood City, CA 94065

#### (Address of principal executive offices, including Zip Code)

#### Registrant's telephone number, including area code: (650) 649-3530

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, $0.0001 par value per share | CHRS | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01 Other Events.
On January 9, 2023, Coherus BioSciences, Inc. (the "Company") announced that the Company entered into a binding term sheet (the "Term Sheet") with Klinge Biopharma GmbH ("Klinge Biopharma") for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea<sup>®</sup> (aflibercept), in the United States. The parties to the Term Sheet expect to execute the definitive agreements contemplated by the Term Sheet (the "Definitive Agreements") and complete the transaction in the first quarter of 2023. Under the Term Sheet, the Company will make a total upfront payment of approximately €30 million, comprised of cash and the Company's common stock, thirty days after the execution of the Definitive Agreements. The Company has also agreed to make other regulatory and launch milestone payments and to make royalty payments based on approximately equal sharing of profits from the sale of FYB203 in consideration for the commercialization rights to FYB203 in the United States.

The material terms of the transaction will be set forth in the Definitive Agreements, which will be included in a subsequent filing when such Definitive Agreements are executed.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 12, 2023 | COHERUS BIOSCIENCES, INC. | COHERUS BIOSCIENCES, INC. |
|  | By: | /s/ McDavid Stilwell |
|  | Name: | McDavid Stilwell |
|  | Title: | Chief Financial Officer |

---